Rybelsus Dosage

Overview of RYBELSUS Formulations

•

​There are two RYBELSUS formulations (i.e., formulation R1 and formulation R2) with different recommended dosages. Refer to recommendations on how to switch from one formulation to another formulation.

o

​RYBELSUS (formulation R1) includes strengths 3 mg, 7 mg and 14 mg.

o

​RYBELSUS (formulation R2) includes strengths 1.5 mg, 4 mg and 9 mg.

•

​These formulations are not substitutable on a mg per mg basis.

•

​Use either RYBELSUS formulation R1or formulation R2; do not use both formulations at the same time.

•

​Do not take more than one tablet per day.

Important Administration Instructions

•

Take RYBELSUS on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS with other liquids besides water.

•

After taking RYBELSUS, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.

•

Swallow tablets whole. Do not split crush or chew.

•

If a dose is missed, skip the missed dose and take the next dose the following day.

Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS Formulations R1 and R2

​RYBELSUS (formulation R1)

​RYBELSUS (formulation R1) includes the following strengths: 3 mg, 7 mg and 14 mg.

​Recommend the following RYBELSUS (formulation R1) dosage to reduce the risk of gastrointestinal adverse reactions:

•

​Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).

•

​Escalation and Maintenance Dosage (Days 31 and beyond):

o

​Days 31 to 60: Increase the dosage to 7 mg orally once daily.

o

​On Day 61 or thereafter, if:

▪

​No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.

▪

​Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.

​RYBELSUS (formulation R2)

​RYBELSUS (formulation R2) includes the following strengths: 1.5 mg, 4 mg and 9 mg.

​Recommend the following RYBELSUS (formulation R2) dosage to reduce the risk of gastrointestinal adverse reactions:

•

​Starting Dosage (Initiation Phase) (Days 1 through 30): The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control).

•

​Escalation and Maintenance Dosage (Days 31 and beyond):

o

​Days 31 to 60: Increase the dosage to 4 mg orally once daily.

o

​On Day 61 or thereafter, if:

▪

​No additional glycemic control is needed maintain the dosage at 4 mg orally once daily.

▪

​Additional glycemic control is needed increase the dosage to 9 mg orally once daily.

Switching Between RYBELSUS (Formulations R1 or R2) or from OZEMPIC to RYBELSUS

​Switching Between RYBELSUS Formulations

•

​Do not switch between RYBELSUS formulations during the initiation phase (Days 1-30).

•

​After 30 days of RYBELSUS treatment (after the initiation phase), patients may switch between RYBELSUS formulations (see Table 1).

•

​When switching between the formulations, initiate the other RYBELSUS formulation the day after discontinuing the previous RYBELSUS formulation.

​Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS Formulations

​*Discontinue this formulation and initiate the alternate formulation the day after

​Switching from OZEMPIC to RYBELSUS (formulation R1) or RYBELSUS (formulation R2)

​Switching from OZEMPIC to RYBELSUS (formulation R1)

•

​One week after discontinuing 0.5 mg of subcutaneous OZEMPIC, start 7 mg or 14 mg of RYBELSUS (formulation R1) orally once daily.

•

​Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg or 2 mg subcutaneously once weekly to RYBELSUS (formulation R1) are not available.

​Switching from OZEMPIC to RYBELSUS (formulation R2)

•

​One week after discontinuing 0.5 mg of subcutaneous OZEMPIC, start 4 mg or 9 mg of RYBELSUS (formulation R2) orally once daily.

•

​Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg or 2 mg subcutaneously once weekly to RYBELSUS (formulation R2) are not available.